뒤로
Karyopharm Therapeutics Inc(KPTI) 가격
KPTI 주가 차트
KPTI 수입
Karyopharm Therapeutics Inc
$5.95
-5.7%
$-0.35
종가: Jan 20, 16:00:00 GMT-5
$5.95
0%
$0
애프터마켓: Jan 20, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-03
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
KPTI의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Karyopharm Therapeutics Inc KPTI의 지난 분기 매출 실적은 어땠나요?
Karyopharm Therapeutics Inc의 매출 추정치는 얼마인가요?
Karyopharm Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Karyopharm Therapeutics Inc는 언제 수익을 보고하나요?
Karyopharm Therapeutics Inc의 예상 수익은 얼마인가요?
Karyopharm Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$6.31
시가
$6.19
일일 범위
$5.89 - $6.32
52주 범위
$3.51 - $10.8
거래량
423.2K
평균 거래량
235.8K
EPS(TTM)
-14.58
배당수익률
--
시가총액
$101.4M
KPTI란 무엇인가요?
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 279 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.